OSR Holdings, Inc.

OSR Holdings, Inc. announced the postponement of its 2026 Annual Meeting of Stockholders, originally scheduled for June 18, 2026. The Board of Directors decided on June 5, 2026, that additional time is needed to evaluate matters related to the meeting and business to be presented. A new date has not yet been established, and the company plans to announce it in a subsequent SEC filing.

OSR Holdings, Inc. has entered into an Asset Purchase Agreement to acquire the VXM01 intellectual property family and related contracts from its indirect subsidiary, Vaximm AG. The purchase price is $30,000,000, payable upon the first milestone payment trigger under a related License Agreement, specifically the completion of a Phase 2 clinical study of VXM01. This transaction is intended to transfer direct ownership of the intellectual property to OSR Holdings, making it the direct beneficiary of future milestone and royalty payments and avoiding potential tax complications in Switzerland.

OSR Holdings, Inc. reported a significant reduction in net loss for the first quarter of 2026, narrowing to $3.47 million from $11.39 million in the prior year. Basic loss per ordinary share improved to $(0.09) from $(1.04). This improvement occurred despite a decrease in net sales and an increase in operating loss. The company also completed the acquisition of Woori-IO Co.,Ltd. during the quarter.

OSR Holdings, Inc. and its subsidiary Vaximm AG entered into a Global Exclusive License Agreement with BCM Europe AG, OSRH's largest shareholder, for the exclusive worldwide license to develop and commercialize VXM01, an oral DNA-based cancer immunotherapy platform. The agreement includes up to $815 million in milestone payments to OSRH. Additionally, BCME and its affiliates pledged 9,974,728 shares of OSRH common stock as collateral for these milestone obligations, effective February 15, 2028. OSRH also gains an equity put option for up to $15 million of its common stock and will acquire VXM01 IP for $30 million.

OSR Holdings, Inc. announced the appointment of Yeiseok Kim as its new Chief Operating Officer, effective April 16, 2026. Mr. Kim, 36, brings medical expertise and experience in cross-border healthcare investments and pharmaceutical licensing from his previous role as a Senior Analyst at a company subsidiary. His compensation package includes a base salary of KRW 240,000,000 per year and participation in the Company's equity-based compensation plan.

OSR Holdings, Inc. has entered into Amendment No. 2 to its Common Stock Purchase Agreement with White Lion Capital, LLC, enhancing its equity financing capabilities. The amendment introduces new purchase mechanisms, including intraday purchase notices allowing the company to sell shares at 90% of the daily volume-weighted average price (VWAP), and fixed purchase notices based on 90% of the VWAP over the three preceding business days. These changes provide OSRH with greater flexibility in accessing capital, with settlement typically occurring within one business day. While offering improved liquidity management, the agreement also includes provisions for price adjustments if the stock falls below a specified threshold, potentially leading to sales at 99% of that threshold price, which could imply dilution for existing shareholders.